One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
How hyperkalemia affects the heart: clinical implications
doi : 10.1093/ndt/gfae287
Volume 40, Issue 6, June 2025
IL-12/23 blocker ustekinumab for the treatment of ANCA-associated glomerulonephritis Free
doi : 10.1093/ndt/gfaf005
The future of glucagon-like peptide-1 receptor agonists in cardiovascular–kidney–metabolic diseases considerations from the ERA Diabesity Working Group Free
doi : 10.1093/ndt/gfaf008
Acquired and genetic drivers of C3 and C5 convertase dysregulation in C3 glomerulopathy and immunoglobulin-associated MPGN
doi : 10.1093/ndt/gfae243
Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN Open Access
doi : 10.1093/ndt/gfae265
Characteristics, treatment and disease burden among stage 3–4 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016–2022 Open Access
doi : 10.1093/ndt/gfae242
Mineralocorticoid receptor antagonism attenuates arteriovenous fistula stenosis by modulating the phenotype of vascular smooth muscle cells Open Access
doi : 10.1093/ndt/gfae247
The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial Open Access
doi : 10.1093/ndt/gfae261
Monocyte/macrophage pyroptosis and C5b-9-induced cyst enlargement in Pkd1−/− mice
doi : 10.1093/ndt/gfae262
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial Open Access
doi : 10.1093/ndt/gfae263
Oral dysbiosis initiates periodontal disease in experimental kidney disease Open Access
doi : 10.1093/ndt/gfae266
Smoking cessation and atherosclerotic cardiovascular events and mortality in chronic kidney disease
doi : 10.1093/ndt/gfae268
Patients with membranous lupus nephritis form two clusters with different prognoses
doi : 10.1093/ndt/gfae295
Genetic testing in a national cohort of adults with chronic kidney disease of unknown origin
doi : 10.1093/ndt/gfae270
Seasonal variations in the association between proteinuria and kidney failure
doi : 10.1093/ndt/gfae278
Disease-modifying anti-nephropathic drugs (DMANDs)—a definition proposed by the Immunonephrology Working Group (IWG) of the European Renal Association (ERA) Open Access
doi : 10.1093/ndt/gfaf033
Normalization dynamics of donor-derived cell-free DNA predicts future kidney transplant rejection
doi : 10.1093/ndt/gfae291
Recovery from acute kidney injury treated with dialysis in patients with multiple myeloma treated with proteasome inhibitors
doi : 10.1093/ndt/gfaf028
Correction to: Long-term outcome of kidney function in patients with ANCA-associated vasculitis Open Access
doi : 10.1093/ndt/gfae201
Correction to: Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group Open Access
doi : 10.1093/ndt/gfae215
